What is Talazoparib?

Talazoparib (Talazoparib) is an inhibitor ofpoly (ADP-ribose) polymerase (PARP). It can blockPARP, a protein involved in the growth, regulation and repair of cancer cells. PARP inhibitors prevent cancer cells from being repaired, which results in cell death and a reduction in tumor growth. PARP inhibitors are used to treat cancers with faulty DNA repair genes, such as BRCA gene mutations. PARP inhibitors are used to treat cancers such as ovarian, fallopian tube, pancreatic, peritoneal, breast and prostate cancers.

Talazopanib has been approved as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, and in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene mutations. Before patients take the drug, doctors will choose to use talazopanib based on the presence of germline BRCA mutations and HRR gene mutations.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).